AVITA Medical Inc (RCEL): Next-Year EPS Estimate 59.35%
As of 2026-09-01, AVITA Medical Inc (RCEL) has a next-year EPS growth estimate of 59.35%. Featured in 5 EPS revision reports, most recently on 2026-08-18.
On 2026-08-20, analyst consensus for RCEL's next-year EPS growth shifted from 59.31% to 59.35% — a positive change of 0.04 percentage points. The revised estimate has been sustained across 12 subsequent trading sessions. Current-year growth is projected at 45.64%.
What's Driving This
The primary driver is the significant upward revision to AVITA Medical’s next-year EPS growth estimate, which analysts raised by 6.25 percentage points on August 19 and have continued to lift, bringing the current estimate to 59.35%. This revision follows AVITA’s record second-quarter performance, which included an 18% revenue surge and a raise to full-year 2026 revenue guidance, alongside positive PermeaDerm study results showing a 70% economic advantage over allograft. The sustained uptick across consecutive trading sessions indicates building momentum from these catalysts.
Generated 2026-09-01 from news as of 2026-09-01
Current Snapshot
- Sector
- Healthcare
- Industry
- Medical Devices
- EPS growth next year
- 59.35%
- EPS growth this year
- 45.64%
- EPS next quarter (est)
- -$0.24
- Last price
- $10.10
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-09-01 | 59.35% | 45.64% | -$0.24 | $10.10 |
| 2026-08-31 | 59.35% | 45.64% | -$0.24 | $10.10 |
| 2026-08-30 | 59.35% | 45.64% | -$0.24 | $10.35 |
| 2026-08-29 | 59.35% | 45.64% | -$0.24 | $10.35 |
| 2026-08-28 | 59.35% | 45.64% | -$0.24 | $10.35 |
| 2026-08-27 | 59.35% | 45.64% | -$0.24 | $10.32 |
| 2026-08-26 | 59.35% | 45.64% | -$0.24 | $10.59 |
| 2026-08-25 | 59.35% | 45.64% | -$0.24 | $10.50 |
| 2026-08-24 | 59.35% | 45.64% | -$0.24 | $9.91 |
| 2026-08-23 | 59.35% | 45.64% | -$0.24 | $10.06 |
| 2026-08-21 | 59.35% | 45.64% | -$0.24 | $10.06 |
| 2026-08-20 | 59.35% | 45.64% | -$0.24 | $10.09 |
| 2026-08-19 | 59.31% | 45.66% | -$0.24 | $10.34 |
| 2026-08-18 | 53.06% | 44.59% | -$0.24 | $9.85 |
| 2026-08-17 | 53.06% | 44.59% | -$0.24 | $7.90 |
| 2026-08-16 | 53.06% | 44.59% | -$0.24 | $7.85 |
| 2026-08-14 | 53.06% | 44.59% | -$0.24 | $7.85 |
| 2026-08-13 | 53.06% | 44.59% | -$0.24 | $8.01 |
| 2026-08-12 | 53.06% | 44.59% | -$0.24 | $8.12 |
| 2026-08-11 | 53.06% | 44.59% | -$0.24 | $8.20 |
| 2026-08-10 | 57.24% | 44.33% | -$0.25 | $7.60 |
| 2026-08-09 | 55.86% | 42.71% | -$0.25 | $7.77 |
| 2026-08-07 | 55.86% | 42.71% | -$0.25 | $7.77 |
| 2026-08-06 | 48.42% | 39.67% | -$0.29 | $4.75 |
| 2026-08-05 | 48.42% | 39.67% | -$0.29 | $4.47 |
| 2026-08-04 | 48.42% | 39.67% | -$0.29 | $4.63 |
| 2026-08-03 | 48.42% | 39.67% | -$0.29 | $4.62 |
| 2026-08-02 | 48.42% | 39.67% | -$0.29 | $4.40 |
| 2026-07-31 | 48.42% | 39.67% | -$0.29 | $4.40 |
| 2026-07-30 | 48.42% | 39.67% | -$0.29 | $4.49 |
Reports Featuring RCEL
- 2026-08-18
Sandisk Surges 32.7% After EPS Revision; ARGX, RCEL Rally
- 2026-07-22
Forward Air (FWRD) surges 25.6% as EPS revision sparks rally
- 2026-07-21
FWRD Leads EPS Revision Surge with 26.7% Gain; AEHR, RCEL Follow
- 2026-07-20
RCEL leads with 27.9% gain on EPS revision; other healthcare stocks follow
- 2026-07-17
RCEL surges 26.9% on EPS revision; COTY, RH, BILL, CVI also gain
Recent News
- AVITA Medical Announces Positive PermeaDerm Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical OutcomesGlobeNewswire
- AVITA Medical to Host Investor Webinar BriefingGlobeNewswire
- AVITA Medical Announces Participation at Canaccord Genuity Growth ConferenceGlobeNewswire
- AVITA Medical Announces Participation at Canaccord Genuity Growth ConferenceGlobeNewswire
- AVITA Medical, Inc. Q2 2026 Earnings Call SummaryMoby
- Avita Medical Shares Surge After Record Second-Quarter PerformanceInvestorsHub
- AVITA Medical Inc (AVHHL) (Q2 2026) Earnings Call Highlights: Revenue Surges 18% to $21. ...GuruFocus.com
- AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow BreakevenGlobeNewswire
- AVITA Medical to Announce Second Quarter 2026 Financial ResultsGlobeNewswire
- AVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn AssociationGlobeNewswire
Screen Performance
Aggregate stats across all 2024 tickers our top-EPS-revision screen has flagged over the past 153 days.
- Median return since detection
- +1.8%
- % of tickers in the green
- 54%
- Median return on winners
- +20.3%
- Large revisions captured
- 1641
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is AVITA Medical Inc's next-year EPS growth estimate?▾
As of 2026-09-01, AVITA Medical Inc (RCEL) has a next-year EPS growth estimate of 59.35%, based on analyst consensus.
When was the latest EPS estimate revision for RCEL?▾
The most recent revision occurred on 2026-08-20, when analysts adjusted the next-year EPS growth estimate from 59.31% to 59.35%.
What sector and industry does AVITA Medical Inc belong to?▾
AVITA Medical Inc operates in the Healthcare sector, specifically the Medical Devices industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. RCEL appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. AVITA Medical Inc (RCEL) appears here because it was detected by our daily top-EPS-revision-performer screen.